|View printer-friendly version|
In his address, Dr. West will provide an update on AgeX product development, and will for the first time present data on the potential use of its proprietary induced Tissue Regeneration (iTRTM) technology in cancer diagnosis and therapy as well as in inducing the destruction of aged cells (a process known as “senolysis”).
A copy of Dr. West’s presentation will be available on AgeX’s website at www.agexinc.com.
About Induced Tissue Regeneration (iTRTM)
The premise behind iTR is that aging, and in turn, diseases of old age, are due to two characteristics that are present in the cells in our body when it is first forming but that are lost with time. These characteristics are:
- Replicative immortality of cells
- Regenerative capacity of cells
Leveraging our assets in pluripotency and bioinformatics, AgeX
scientists have performed research in cellular immortality and
regenerative biology, comparing cells in the first stages of life with
those in old age. In 2010, while at
The AgeX scientific team subsequently extended this research to determine whether reprogramming can be modified to only reverse the aging of cells back to a regenerative state, not back to pluripotency. For example, the team has utilized the gene COX7A1 as a marker of cells that have lost regenerative potential. AgeX’s proprietary formulation AGEX-iTR1547 has demonstrated initial capability of reducing the expression of the marker gene COX7A1 and is currently performing research to optimize a potential pharmaceutical preparation to reverse the aging of human tissues and thereby restore regenerative potential.
When implemented in vivo, this partial reprogramming, or iTR, would be expected to induce tissue regeneration, and when combined with telomerase, could modulate both cellular immortality and regenerative biology for therapeutic effect.
In addition, RenelonTM, a first-generation product candidate under development at AgeX, utilizes a repurposed drug formatted in the company’s HyStem® hydrogels, and is planned for initial development as a device for topical application. While not capable of fully transporting cells back to a regenerative state, the anticipated ability of Renelon to impart scarless tissue repair could provide significant benefits to patients.
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of